Saturday, July 11, 2026

pharma · Chronic Obstructive Pulmonary Disease · Tuberculosis

Anhui Huaheng Biotechnology

Anhui Huaheng Biotechnology clinical programs — 2 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Hefei, CN HQ
2005 Founded
32 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Hefei, CN
Founded
2005
Employees
32
Programs
2
Drugs
6
Patents
0
Intelligence · Clinical Programs

Anhui Huaheng Biotechnology projects

2 ClinicalTrials.gov programs sponsored by Anhui Huaheng Biotechnology.

Anhui Huaheng Biotechnology has 2 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Hemay005 tablet

    Anhui Hemay Pharmaceutical Co., Ltd

    Chronic Obstructive Pulmonary Disease

    phase 1 small molecule completed

    1 trial
  2. Purified Protein Derivative of BCG(BCG-PPD)

    Anhui Hemay Pharmaceutical Co., Ltd

    Tuberculosis

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Anhui Huaheng Biotechnology have?

2 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.